Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the globe and is a leading generic manufacturer in the southern hemisphere. Aspen has businesses in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States. Acquisitions announced in 2013 will further extend the Group’s emerging market presence to the Commonwealth of Independent States, comprising Russia and the former Soviet Republics as well as to Central and Eastern Europe.
Aspen was the world’s first pharmaceutical company to pioneer the manufacture and development of generic antiretrovirals (ARVs) and launched Africa’s first generic ARV in August 2003. Aspen has received US Food and Drug Administration accreditation for the manufacture of specific generic ARVs at its Port Elizabeth-based facility and was the world’s first pharmaceutical manufacturer to be granted voluntary generic ARV licenses from selected leading multinationals.
In 2004, The Clinton Foundation chose Aspen as the first southern hemisphere company to manufacture generic ARVs for their program. Aspen presently provides ARVs to an estimated 600 000 HIV/Aids patients across the African continent.